AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Full commercial rights to GVAX vaccines reacquired.
2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Cell Genesys, Inc., (NASDAQ:CEGE) announced that it has reacquired full commercial rights to GVAX lung cancer vaccines following the termination of its remaining license agreement with the pharmaceutical division of Japan Tobacco, Inc. (JT).
As a result, Cell Genesys now holds all worldwide commercial rights to its entire portfolio of GVAX cancer vaccine products.
Given the scope of the company's plans for the next clinical trials of GVAX lung cancer vaccine, as well as the anticipated funding from the U.S. National Cancer Institute for one of those trials, Cell Genesys expects the near-term revenue impact from ending the agreement with JT to be minimal.
In June 2002 at the International Lung Cancer Congress, Cell Genesys presented the final results of a multicenter phase I/II trial of GVAX lung cancer vaccine. These results demonstrated complete tumor regressions in three of 33 patients (9%) with advanced non-small cell lung cancer (NSCLC) who received the vaccine after failing prior radiation and/or chemotherapy, as well as stable disease or minor responses in another seven patients (21%). The median survival of all treated patients was approximately 8 months compared with 5.7-7 months reported for taxol chemotherapy and approximately 4.6 months for best supportive care.
In addition, patients with the bronchoalveolar carcinoma (BAC) subtype of NSCLC appeared to be particularly responsive to GVAX lung cancer vaccine treatment. As a result, the company recently announced its intention to conduct two phase II trials in patients with BAC prior to initiating a broad phase III trial in all types of NSCLC. One of the two BAC trials will be sponsored and conducted by the National Cancer Institute's Southwest ...
- Cell Genesys Announces Initiation of Phase 2 Trial of GVAX(R) Lung Cancer...
- Press release article from: PR Newswire June 28, 2004 700+ words
...chief operating officer of Cell Genesys. "Bronchoalveolar lung cancer is generally less responsive...specific GVAX(R) lung cancer vaccines for clinical trials. Cell Genesys is now manufacturing GVAX(R) lung cancer vaccines in its 35,000...
- Cell Genesys Confirms Publication of Scientific Paper on GVAX(R) Lung Cancer...
- Press release article from: PR Newswire February 20, 2004 700+ words
...clinical trial of Cell Genesys' GVAX(R) lung cancer vaccine trial...of Cancer. Cell Genesys is currently...GVAX(R) lung cancer vaccine to...small-cell lung cancer and is expected...quarter of 2004. Cell Genesys is focused...
- Cell Genesys Comments on CBS Segment Highlighting Preliminary Clinical Result...
- Press release article from: PR Newswire November 16, 2000 700+ words
...result from Cell Genesys' ongoing Phase...GVAX(R) lung cancer vaccine clinical...is treated. Cell Genesys plans to develop...product for lung cancer since other...participate in Cell Genesys' GVAX(R) lung cancer vaccine trials...
- Cell Genesys Advances GVAX(R) Lung Cancer Vaccine To Multicenter Phase I/II...
- Press release article from: PR Newswire April 7, 2000 700+ words
...cancers, including lung cancer. Cell Genesys is developing GVAX...in December 1998. Cell Genesys' GVAX(R) lung cancer vaccine is a patient...how to participate in Cell Genesys' GVAX(R) lung cancer vaccine trials can...
- Cell Genesys to Start Lung Cancer Vaccine Trial in Memphis, Tenn.
- Newspaper article from: The Commercial Appeal (Memphis, Tennessee) (via Knight-Ridder/Tribune Business News) March 6, 2002 700+ words
...That's when Cell Genesys plans to start...for its GVAX lung cancer vaccine from...Stephen Sherwin, Cell Genesys chairman and...26 latestage lung cancer patients for...wonderful benefit." Cell Genesys chose to operate...
- Cell Genesys Reacquires Full Commercial Rights to GVAX(R) Lung Cancer Vaccines.
- Press release article from: PR Newswire October 18, 2002 700+ words
...International Lung Cancer Congress, Cell Genesys presented the...on GVAX(R) lung cancer vaccines. Under...modified agreement, Cell Genesys would pay JT...for GVAX(R) lung cancer vaccine products. Cell Genesys' GVAX(R...
- Cell Genesys Secures Memphis Facility for Manufacturing of Patient-Specific...
- Press release article from: PR Newswire February 12, 2002 700+ words
...sets the stage for Cell Genesys' product development...for GVAX(R) lung cancer vaccines which...surgical biopsy. In Cell Genesys' initial Phase II GVAX(R) lung cancer vaccine trial...received GVAX(R) lung cancer vaccine following...of 12 months. ...
- Cell Genesys Initiates Second Multicenter Phase I/II Trial of GVAX(R) Lung...
- Press release article from: PR Newswire June 21, 2001 700+ words
...operating officer of Cell Genesys. "We are now...both prostate and lung cancer beginning in late...type of vaccine. Cell Genesys is evaluating two...patient-specific lung cancer vaccine one of...manufactured at Cell Genesys. This new format of GVAX(R) ...
Source: HighBeam Research, Full commercial rights to GVAX vaccines reacquired.